Cargando…

Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B

The orally available anti‐hepatitis C virus (HCV) drug simeprevir exhibits nonlinear pharmacokinetics at the clinical doses due to saturation of cytochrome P450 (CYP) 3A4 metabolism and organic anion transporting peptide (OATP) 1B mediated hepatic uptake. Additionally, simeprevir increases exposures...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakayama, Shinji, Toshimoto, Kota, Yamazaki, Shinji, Snoeys, Jan, Sugiyama, Yuichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583237/ https://www.ncbi.nlm.nih.gov/pubmed/37667529 http://dx.doi.org/10.1002/psp4.13023

Ejemplares similares

PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3
por: Yoshikado, Takashi, et al.
Publicado: (2018)

Physiologically‐Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter–Mediated Interactions Between Metformin and Cimetidine
por: Nishiyama, Kotaro, et al.
Publicado: (2019)

Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects
por: Toshimoto, Kota, et al.
Publicado: (2017)

Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug‐Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects
por: Asaumi, Ryuta, et al.
Publicado: (2018)

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications
por: Marra, Fiona, et al.
Publicado: (2018)

Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment
por: Ouwerkerk-Mahadevan, Sivi, et al.
Publicado: (2015)

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir
por: Ouwerkerk-Mahadevan, Sivi, et al.
Publicado: (2015)

Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs
por: Mori, Daiki, et al.
Publicado: (2020)

Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs
por: Mochizuki, Tatsuki, et al.
Publicado: (2022)

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation
por: Barnett, Shelby, et al.
Publicado: (2018)

Quantitative Prediction of OATP‐Mediated Drug‐Drug Interactions With Model‐Based Analysis of Endogenous Biomarker Kinetics
por: Yoshida, Kenta, et al.
Publicado: (2018)

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients
por: Wang, Zhiqi, et al.
Publicado: (2019)

Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin
por: Rose, R H, et al.
Publicado: (2014)

Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene
por: Trdan Lušin, Tina, et al.
Publicado: (2012)

Physiologically‐based pharmacokinetic modeling to evaluate in vitro‐to‐in vivo extrapolation for intestinal P‐glycoprotein inhibition
por: Yamazaki, Shinji, et al.
Publicado: (2021)

Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker
por: Zhang, Miao, et al.
Publicado: (2022)

Simeprevir for the treatment of hepatitis C virus infection
por: Izquierdo, Laure, et al.
Publicado: (2014)

In vitro susceptibility of human Blastocystis subtypes to simeprevir
por: Mossallam, Shereen F., et al.
Publicado: (2021)

Simeprevir restores the anti-Staphylococcus activity of polymyxins
por: Wu, Yuan, et al.
Publicado: (2023)

Corrigendum to: Physiologically‐based pharmacokinetic modeling to evaluate in vitro‐to‐in vivo extrapolation for intestinal P‐glycoprotein inhibition
por: Yamazaki, Shinji, et al.
Publicado: (2022)

Expanded Physiologically‐Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction
por: Asaumi, Ryuta, et al.
Publicado: (2019)

Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease
por: Takita, Hiroyuki, et al.
Publicado: (2022)

Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations
por: Li, R, et al.
Publicado: (2014)

Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine
por: Jang, Yeonseo, et al.
Publicado: (2023)

Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel
por: Schilling, Uta, et al.
Publicado: (2020)

Simultaneous spectrofluorimetic determination of remdesivir and simeprevir in human plasma
por: El Sharkasy, Mona E., et al.
Publicado: (2022)

Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters
por: Ahmad, Amais, et al.
Publicado: (2021)

Pharmacokinetics, safety, and tolerability of the 2‐ and 3‐direct‐acting antiviral combination of AL‐335, odalasvir, and simeprevir in healthy subjects
por: Kakuda, Thomas N., et al.
Publicado: (2018)

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection
por: Bourgeois, Stefan, et al.
Publicado: (2017)

Structure of human drug transporters OATP1B1 and OATP1B3
por: Ciută, Anca-Denise, et al.
Publicado: (2023)

Relationship of hemoglobin level and plasma coproporphyrin‐I concentrations as an endogenous probe for phenotyping OATP1B
por: Suzuki, Yosuke, et al.
Publicado: (2021)

Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study
por: Kalluri, Hari V., et al.
Publicado: (2020)

Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions
por: Mochizuki, Tatsuki, et al.
Publicado: (2022)

Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype‐Guided Dosing of Tamoxifen
por: Nakamura, Toshimichi, et al.
Publicado: (2018)

Physiologically‐Based Pharmacokinetic Modeling Approach to Predict Rifampin‐Mediated Intestinal P‐Glycoprotein Induction
por: Yamazaki, Shinji, et al.
Publicado: (2019)

Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1
por: Nies, Anne T, et al.
Publicado: (2013)

Differential Preincubation Effects of Nicardipine on OATP1B1- and OATP1B3-Mediated Transport in the Presence and Absence of Protein: Implications in Assessing OATP1B1- and OATP1B3-Mediated Drug–Drug Interactions
por: Kayesh, Ruhul, et al.
Publicado: (2023)

Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?
por: Yamazaki, Shinji, et al.
Publicado: (2022)

Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions
por: Alam, Khondoker, et al.
Publicado: (2018)

Transcriptional Regulation of Liver-Type OATP1B3 (Lt-OATP1B3) and Cancer-Type OATP1B3 (Ct-OATP1B3) Studied in Hepatocyte-Derived and Colon Cancer-Derived Cell Lines
por: Haberkorn, Bastian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n19t7ooce30obpc0b0bpv2gooh